Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
3.800
0.00 (0.00%)
Sep 11, 2026, 4:00 PM EDT - Market closed
Fulcrum Therapeutics Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Fulcrum Therapeutics stock has a consensus rating of "Hold" and an average price target of $3.50. The average 1-year stock price forecast is 7.89% lower than the current stock price, while the lowest is $3.00 (-21.05%) and the highest is $4.00 (+5.26%).
Price Target: $3.50 (-7.89%)
Analyst Consensus: Hold
Price Target
Chart* Price targets were last updated on Aug 7, 2026.
Analyst Ratings
The average analyst rating for Fulcrum Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 5 | 5 | 5 |
| Sell | 1 | 1 | 1 | 3 | 2 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 8 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Financial | Truist Financial | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Aug 18, 2026 |
| Bank of America Securities | Bank of America Securities | Sell Reiterates $3 | Sell | Reiterates | $3 | -21.05% | Aug 7, 2026 |
| J.P. Morgan | J.P. Morgan | Sell Downgrades n/a | Sell | Downgrades | n/a | n/a | Jun 2, 2026 |
| H.C. Wainwright | H.C. Wainwright | Hold Downgrades $25 → $3 | Hold | Downgrades | $25 → $3 | -21.05% | Jun 2, 2026 |
| Leerink Partners | Leerink Partners | Hold Downgrades $24 → $4 | Hold | Downgrades | $24 → $4 | +5.26% | Jun 2, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.66
from -1.18
EPS Next Year
-0.49
from -0.66
EPS and Forward PE are based on non-GAAP adjusted numbers.